May 2, 2013

CYCLOSET (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm

CYCLOSET is recommended for dual therapy for patients with entry HbA1c ≥ 7.5% SAN DIEGO & TIVERTON, R.I. --(BUSINESS WIRE)--...
Read More
March 6, 2013

Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes

Experts conclude that favorable cardiovascular profile of CYCLOSET suggests it may be useful in the treatment of patients with type...
Read More
January 23, 2013

Santarus and VeroScience Announce Publication of Positive Data from Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study

CYCLOSET add-on therapy provided significant improvement in glycemic control versus placebo in patients with type 2 diabetes poorly controlled on...
Read More
November 13, 2012

Santarus and VeroScience Announce Publication of New Analysis of CYCLOSET (bromocriptine mesylate) Cardiovascular Data in the Journal of the American Heart Association

In assessing cardiovascular safety in type 2 diabetes subjects, CYCLOSET demonstrated a significant 52% relative risk reduction in cardiovascular events...
Read More